Get the Stockscreener App
292.01
1.32%
-3.92
After Hours:
292.01
Alnylam Pharmaceuticals Inc stock is traded at $292.01, with a volume of 1.34M.
It is down -1.32% in the last 24 hours and up +6.62% over the past month.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.
See More
Previous Close:
$295.93
Open:
$294.33
24h Volume:
1.34M
Relative Volume:
1.64
Market Cap:
$37.49B
Revenue:
$2.34B
Net Income/Loss:
$-72.94M
P/E Ratio:
-70.53
EPS:
-4.14
Net Cash Flow:
$318.87M
1W Performance:
+3.07%
1M Performance:
+6.62%
6M Performance:
+102.21%
1Y Performance:
+80.49%
1-Day Range:
$288.34
$295.38
1-Week Range:
$283.75
$304.39
52-Week Range:
$141.97
$304.39
Alnylam Pharmaceuticals Inc Stock (ALNY) Company Profile
Name
Alnylam Pharmaceuticals Inc
Sector
Industry
Phone
(617) 551-8200
Address
675 WEST KENDALL STREET, CAMBRIDGE, MA
Alnylam Pharmaceuticals Inc Stock (ALNY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-16-24 | Upgrade | Goldman | Neutral → Buy |
| Feb-16-24 | Downgrade | Goldman | Buy → Neutral |
| Feb-15-24 | Initiated | Wolfe Research | Peer Perform |
| Dec-08-23 | Initiated | Wells Fargo | Equal Weight |
| Oct-11-23 | Downgrade | Oppenheimer | Outperform → Perform |
| Sep-29-23 | Initiated | Raymond James | Outperform |
| May-05-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Apr-26-23 | Initiated | SMBC Nikko | Neutral |
| Mar-21-23 | Initiated | Bernstein | Outperform |
| Jan-18-23 | Initiated | Canaccord Genuity | Buy |
| Sep-09-22 | Resumed | Morgan Stanley | Equal-Weight |
| Jul-13-22 | Initiated | Cantor Fitzgerald | Neutral |
| Jun-27-22 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-07-22 | Initiated | William Blair | Outperform |
| Apr-25-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Mar-01-22 | Initiated | Citigroup | Buy |
| Feb-03-22 | Upgrade | Guggenheim | Neutral → Buy |
| Jan-03-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Nov-22-21 | Upgrade | Goldman | Neutral → Buy |
| Nov-22-21 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-01-21 | Upgrade | Oppenheimer | Perform → Outperform |
| Oct-04-21 | Upgrade | UBS | Neutral → Buy |
| Aug-04-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Feb-22-21 | Downgrade | Guggenheim | Buy → Neutral |
| Feb-12-21 | Downgrade | Citigroup | Buy → Neutral |
| Feb-12-21 | Reiterated | H.C. Wainwright | Buy |
| Jan-25-21 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Sep-30-20 | Resumed | Berenberg | Hold |
| Sep-08-20 | Initiated | Citigroup | Buy |
| Aug-11-20 | Downgrade | Oppenheimer | Outperform → Perform |
| May-13-20 | Initiated | RBC Capital Mkts | Sector Perform |
| May-07-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Apr-24-20 | Resumed | Evercore ISI | Outperform |
| Mar-19-20 | Initiated | Berenberg | Buy |
| Dec-19-19 | Reiterated | Chardan Capital Markets | Buy |
| Nov-20-19 | Initiated | Oppenheimer | Outperform |
| Nov-13-19 | Initiated | BofA/Merrill | Buy |
| May-23-19 | Resumed | Goldman | Neutral |
| Apr-12-19 | Initiated | Evercore ISI | Outperform |
| Mar-06-19 | Upgrade | Evercore ISI | In-line → Outperform |
| Mar-05-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jan-23-19 | Initiated | UBS | Neutral |
| Oct-01-18 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-13-18 | Reiterated | Stifel | Buy |
| Aug-07-18 | Upgrade | Stifel | Hold → Buy |
| May-04-18 | Reiterated | Stifel | Hold |
| Mar-28-18 | Initiated | Evercore ISI | In-line |
View All
Alnylam Pharmaceuticals Inc Stock (ALNY) Latest News
TD Cowen Boosts Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target to $371.00 - MarketBeat
Alnylam Stock Up on Cardiomyopathy Drug Regulatory Filing in the EU - MSN
Avadel Obtains FDA Nod for Label Expansion Of Narcolepsy Drug Lumryz - Benzinga
Alnylam shares hold Buy rating on successful launch anticipation By Investing.com - Investing.com UK
Alnylam Pharmaceuticals' (ALNY) Buy Rating Reiterated at HC Wainwright - MarketBeat
Alnylam Canada Signs Letter of Intent from pan-Canadian Pharmaceutical Alliance for the Public Reimbursement of AMVUTTRA® For The Treatment Of Hereditary Transthyretin-Mediated (hATTR) Amyloidosis In Adults - Quantisnow
High Growth Tech Stocks to Watch in October 2024 - Simply Wall St
Swedbank AB Boosts Stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat
Moderna Wants Fees For 'Frivolous' COVID-19 Vax Suit - Law360
Are Medical Stocks Lagging Alnylam Pharmaceuticals (ALNY) This Year? - Yahoo Finance
Hypertension Clinical Trials 2024: FDA Approvals, Medication, - openPR
Alnylam to Webcast Conference Call Discussing Third Quarter 2024 Financial Results - StockTitan
Leerink Partnrs Research Analysts Cut Earnings Estimates for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat
Leerink Partnrs Issues Pessimistic Outlook for ALNY Earnings - MarketBeat
Alnylam Pharmaceuticals (NASDAQ:ALNY) Coverage Initiated at Scotiabank - MarketBeat
Alnylam seeks EMA nod for heart-related therapy - Investing.com
Alnylam seeks EMA nod for heart-related therapy By Investing.com - Investing.com UK
Alnylam Submits Regulatory Application to the European Medicines Agency for Vutrisiran for the Treatment of ATTR Amyloidosis with Cardiomyopathy - StockTitan
Cwm LLC Has $1.86 Million Stock Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat
Scotiabank Initiates Coverage of Alnylam Pharmaceuticals (ALNY) with Sector Outperform Recommendation - MSN
Alnylam stock soars to all-time high of $287.88 amid robust growth - Investing.com Canada
Alnylam Pharmaceuticals (NASDAQ:ALNY) Sets New 12-Month High on Analyst Upgrade - MarketBeat
Sanctuary Advisors LLC Takes $578,000 Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat
Bank of America Increases Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target to $314.00 - MarketBeat
Gene Silencing Market to Expand with Significant CAGR by 2034 |Alnylam Pharmaceuticals, Benitec Biopharma, Arrowhead Pha – IndiaPolitics.com - IndiaPolitics.com
Alnylam’s founder brings in a $135M series A for City Therapeutics - BioWorld Online
Alnylam Pharmaceuticals stock bolstered by updated prevalence estimates exceeding 300K - Investing.com Canada
Perpetual Ltd Buys Shares of 4,112 Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat
Why Ionis Pharmaceuticals Inc Tanked and Alnylam Pharmaceuticals, Inc. Is Soaring Today - The Pantagraph
Alnylam Submits sNDA for Vutrisiran for Treatment of ATTR-CM - MD Magazine
Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock Rating Reaffirmed by Chardan Capital - MarketBeat
Alnylam shares hold as Oppenheimer sees limited upside By Investing.com - Investing.com UK
BofA Securities reiterates buy rating on Alnylam stock, highlights Amvuttra launch strategy - Investing.com UK
Primary Hyperoxaluria Market Poised for Significant Growth - openPR
Primary Hyperoxaluria Market Poised for Significant Growth from 2024 to 2034, Reports DelveInsight | Dicerna Pharmaceuticals, Inc., Allena Pharmaceuticals, Biocodex, Alnylam Pharmaceuticals - The Globe and Mail
Alnylam Pharmaceuticals Insiders Sell US$5.0m Of Stock, Possibly Signalling Caution - Simply Wall St
Alnylam Pharmaceuticals' (ALNY) Buy Rating Reiterated at Needham & Company LLC - MarketBeat
Biotech Eyes Early Entry As Several Factors Could Unleash Shares - MSN
Protein prediction wins chemistry Nobel; Alnylam submits an all-important drug application - BioPharma Dive
Alnylam files sNDA for new amyloidosis treatment - Investing.com
Alnylam Seeks Accelerated FDA Approval of Amvuttra for Rare Heart Disease - Morningstar
Alnylam files sNDA for new amyloidosis treatment By Investing.com - Investing.com UK
Alnylam Submits Supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration for Vutrisiran for the Treatment of Transthyretin Amyloidosis with Cardiomyopathy - Business Wire
We Built This City: Maraganore’s Latest Start-Up Aims For Smaller RNAi Drugs - Scrip
City Therapeutics Launches with $135 Million Series A Financing - citybiz
Alnylam's founding CEO is back with another RNAi-based medicines company - The Business Journals
Startup led by John Maraganore raises $135M to build ‘future of RNAi’ - BioPharma Dive
Alnylam Pharmaceuticals Insiders Sold US$5.0m Of Shares Suggesting Hesitancy - Yahoo Finance
City Therapeutics Launches with $135 Million Series A Financing to Lead the Future of RNAi-based Medicine - Yahoo Finance
4,744 Shares in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Bought by Healthcare of Ontario Pension Plan Trust Fund - MarketBeat
Creative Planning Increases Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat
Alnylam Pharmaceuticals Inc Stock (ALNY) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.81%
0.43%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):